Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. Lung and liver cancers were among the top three leading causes of cancer death in 2020 with 1.8 million and 830.000 deaths, respectively. On the other hand, soft tissue sarcomas are relatively uncommon cancers diagnosed in about 1% of all adults, but much more common in children and young adults, accounting for 7–10% of paediatric malignancies; they are an important cause of death in the 14–29 years age group. Interventional Oncology involves miniaturized instruments (biopsy needles, ablation electrodes, intravascular catheters) and minimally-invasive access, guided by imaging techniques (X-ray, ultrasound, computed tomography, magnetic resonance imaging) – to target cancer with ablative or localized drug delivery strategies. Interventional Oncology can be used as a stand-alone approach, or in combination with the other approaches (‘pillars’) to enhance treatment efficacy. While cancer survival has significantly improved over time through innovations in each individual pillar, our current understanding of cancer now leads us to an intertwining of pillars and multimodal care pathways: Interventional Oncology is uniquely suited to leverage and enhance the effects of the conventional therapy pillars, while reducing the burden on the healthcare system. IMAGIO will leverage Interventional Oncology in the clinical setting to improve the cancer survival outcomes, through minimally invasive, efficient, and affordable care. We will deliver four complete, multimodal care pathways for two of the most aggressive cancers (liver, lung) and one of the most debilitating when treated with current approaches (sarcoma): 1. Multimodal interventional imaging for fast and precise radioembolization therapy of liver cancer; 2. Multimodal ablation therapy of liver cancer; 3. Multimodal diagnosis and therapy in early-stage lung cancer; and 4. Multimodal MR-HIFU-enabled therapy for abdominal sarcoma. IMAGIO will mature the next-generation interventional imaging across the full spectrum, from pre-clinical developments to impact validation in clinical trials. Expertise on Interventional Oncology and immunotherapy will be leveraged from pioneering clinical research centres and leading industry covering the full value chain of oncological care, as well as cancer patient and professional organisations. Such synergetic partnerships will accelerate the impact of the technologies and transform the way healthcare solutions are delivered, providing access to safe, fast, and effective care. By focusing on the local delivery of therapy, IMAGIO will drive the substitution of conventional higher dose systemic alternatives or invasive surgical approaches, thereby accelerating recovery, reducing complication rates and the number of patient visits.

aMUSE plans to strengthen and extend the collaboration between EU and US researchers to carry out cutting-edge searches for New Physics (NP) in the muon sector, while promoting the development of next generation muon accelerators. The project finds its roots in the previous MUSE network based at the Muon Campus of FNAL, USA. Here, the Muon (g-2) experiment aims to solve the long-standing muon anomaly puzzle and related NP implications collecting a twenty-fold increase in statistics compared to its predecessor. A high-profile discovery path for the search of charged Lepton Flavour Violation (cLFV) will be exploited by the Mu2e experiment, whose goal is to improve the discover sensitivity for the as yet unseen muon-to-electron conversion by four orders of magnitude, reaching mass scales of 10^4 TeV/c^2. aMUSE promotes an ambitious extension of the Muon Campus activities. Its R&D programs will exploit the future phase of Mu2e-II with an upgraded proton beam providing a ten-fold increase in muon yield. aMUSE aims to design and develop state-of-the-art detectors to face this challenge. At this high intensity frontier, aMUSE will explore the design of a beam line extension to seed the birth of new generation experiments searching for cLFV muon decays as a possible alternate running to Mu2e-II. Its final goal is to vastly improve sensitivity with respect to currently existing or proposed facilities and promote the integration of EU groups in developing accelerator and detector strategies. aMUSE further provides an excellent platform for an ambitious EU-US network to advance the development of muon beams. Low and high energy research is synergistic: muon cooling is fundamental to both high-energy muon collisions and low-energy high-intensity muon beams. The US longstanding competences in the study of muon beam technologies will be integrated with the experience of EU researchers, creating a unique opportunity for the advancement of a challenging and promising project.